Kevzara Fails in Phase 3 Clinical Trial
Kevzara (Sarilumab), a promising rheumatoid-arthritis drug with anti-inflammatory benefits failed to show any significant improvement in Covid-19 patients according to Regeron and Sanofi press releases regarding their phase 3 clinical trial.
Chiefly, it was reported that the use of 400 mg of Kevzara in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints of the study when the treatment was added to best supportive care.
Kevzara binds specifically to the IL-6 receptor, and has been shown in other studies to inhibit IL-6-mediated signaling. Kevzara was being investigated for its ability to reduce the overactive inflammatory immune response associated with COVID-19 based on evidence of markedly elevated levels of IL-6 in critically ill patients infected with coronaviruses.
Kevzara is somewhat similar in function to Actemra (tocilizumab). Earlier this month, the first randomized test using Actemra also failed to show significant results in reducing transitions to ICU or overall mortality.
The search for additional mortality reducing anti-inflammatory's is still ongoing and many new candidates are still emerging, with dexamethasone being the most recently uncovered drug to show conclusive clinical benefits.